about
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)Zika and Microcephaly: Case-control StudyRandomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease VaccineMelatonin versus Placebo in Breast CancerAURORA trialVicriviroc in HIV-Treatment Experienced SubjectsVaccine Treatment for Surgically Resected Pancreatic CancerCellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the LungCarboxyamidotriazole in Treating Patients With Advanced Kidney CancerVaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV MelanomaPhase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal SeedingDenileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic CancerVaccine Treatment for Hormone Refractory Prostate CancerStem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple MyelomaImiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the SkinAdoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung MetastasesPhase II Trial of EOquin in High-risk Superficial Bladder CancerCombination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerStudy on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and NeckVaccine Treatment for Advanced Non-Small Cell Lung CancerChemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian CancerA Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian CancerAn Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of DarolutamideIntrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With MedulloblastomaCombination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic CancerA Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell SupportEvaluation of Factors in Human Brain TumorsImmunotherapy in Treating Patients With Resected Liver Metastases From Colon CancerRadioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid CancerRadioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast CancerA Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic CancerPhase II Trial of Allovectin-7® for Metastatic MelanomaCellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal CancerT Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety StudySipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate CancerA Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their TumorPhase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in GlioblastomaDendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
P8005
Q26780915-AE1A1F81-9A12-4DE5-99CE-6BCB30EAB4ACQ26780920-55FD7ADD-A0DF-4C9E-9F5C-531AAB04F627Q28837195-2E3F0827-30FA-40A3-94BC-E97D6B398AA2Q28922621-5E6FDBD4-2DA3-4317-989C-16E83E2938C8Q4654994-095DFB38-3C3E-494B-A2D5-C4BFDE2AFC36Q4654994-FF8FAA4D-BE2B-48AC-9483-FA2D44116F0FQ47683789-89517AF5-582D-4D8E-957C-78859C533D37Q58391323-7CDE25A3-D0F2-4E86-8D36-3925632BFC6CQ58402915-8F46D0C6-DB0A-4D46-9EFE-4E77711713F0Q58407313-C652685E-EED5-400A-B9CF-83740FB7C480Q58407324-128CF4EE-310B-4991-923E-AF878668CE4DQ58407411-2E6DB264-0CE4-47BC-ADC9-BB3873296C8DQ58407411-38F8030F-FF6D-46A6-B3AC-61EE2E58BC5CQ58407413-C6D4B030-2104-452E-AC29-1DEF6229670BQ58407430-68EE7AFE-994C-47AA-A86D-82040D958573Q58407442-2A72E57C-7EEE-40F2-9782-599A437899BDQ58407443-8D13A21A-994F-4E1F-8954-5B01DDC2651EQ58407444-99BCC2DF-C794-4049-AC99-C9ECF1D758B0Q58407451-391118AB-89E0-4FF5-9C30-C3E169FE2A0AQ58407453-B7779FB5-9465-4FFF-BF46-304FDBDD541AQ58407496-638392C0-3E54-4FB5-95AB-78DEE7949497Q58407503-D4C2A94F-E716-4847-9867-1D2887D20819Q58407507-18728F0F-905B-4B33-B806-75D331D5B18AQ58407518-028C460B-C2C4-4397-9B9E-B6BC5960E2EFQ58407546-9CB7A97C-D46E-4D26-A84B-CADC4E8B4808Q58407638-62212EFC-4C39-413D-ABAF-8F9CD375FEBDQ58407655-1D19DE79-2B63-4CAB-AAD2-034262B13A4EQ58407657-289E6F0D-5BD8-4D27-8082-FEBA532356B0Q58407719-0B2B8746-AF4A-42FE-8899-999E992F813AQ58407719-85B162BE-4A0D-4DB9-B4CF-15D6E1C38936Q58824340-64F98E43-F743-4B00-8D6A-627C6435EDACQ58843819-A9A6A8E4-54F7-48EB-98DA-7A9FDCCBC301Q58843819-E67D62FB-EF0F-429F-BDDA-ED248DF70309Q58844157-039299AA-FD54-4E13-9474-B8568611340CQ58844184-2D9461AF-796B-4CC2-BCD1-7284E1A9CE01Q58844194-0FEA9C31-729F-48F7-92D7-333404EDDA35Q58844219-4A94EE7B-7A20-439E-A08F-8A4B2937B589Q58844228-BC6AF01D-98EC-4863-A1C6-E2B29E75697CQ58844289-B5503317-4992-4874-B106-B75EBF6CAFF8Q58844601-590D206E-6E33-42A4-BAA8-D8F22B16127D
P8005
description
recruitment status in clinical trials
@en
name
completat
@ca
completed
@en
type
label
completat
@ca
completed
@en
prefLabel
completat
@ca
completed
@en